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In depressed patients, antidepressant resistance has been associated with dysregulation
of the hypothalamus-pituitary-adrenal (HPA) axis but the underlying mechanisms are poorly
understood. The scope of this study was to try to create HPA-related antidepressant
resistance in mice and to investigate adult hippocampal neurogenesis as a putative
mechanism of antidepressant resistance. Mice were subjected to a 9 week Unpredictable
Chronic Mild Stress (UCMS). After a 2 weeks drug-free period, mice were segregated
in two groups, according to the percentage of corticosterone suppression after
dexamethasone injection: High suppression (HS) and Low suppression (LS) mice. From
the 5th week onwards, fluoxetine at a dose of 15 mg/kg (i.p.) was administered daily
and at the end of 8th week, a battery of behavioral tests assessing the emotional,
cognitive, and motor aspects of UCMS-induced depressive-like behavior was applied.
Results show that fluoxetine-induced antidepressant effects were observed with higher
amplitude in HS when compared to LS on various behavioral phenotypes, like coat state,
novelty suppression of feeding, splash test and nest test. The same profile was found
concerning the immunohistochimical analysis of ki-67 positive cells in the dentate gyrus
of the hippocampus, which is a marker of neuronal proliferation, but not for doublecortin
labeling. This suggests that the failure of fluoxetine to induce antidepressant effects may
be associated to the poor ability of the compound to stimulate cell proliferation in the
hippocampus.
Keywords: antidepressant resistance, fluoxetine, corticosterone, hippocampal neurogenesis, unpredictable chronic
mild stress, dexamethazone suppression
INTRODUCTION
Major depressive disorder, the most common psychiatric
disorder, is estimated to affect around 120 million people
in the world (Hashimoto, 2011), with an estimated lifetime
prevalence of about 17% in the USA (Kessler et al., 2005).
Depressive disorder is characterized by depressed mood, anhe-
donia and difficulties in concentration (American Psychiatric
Association, 1994; Perahia et al., 2009; Willner et al., 2013).
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxe-
tine are the most common form of medication to treat major
depression. However, approximately 50% of patients do not
respond adequately to treatment with conventional antidepres-
sants (Trivedi et al., 2006; Fava et al., 2008). Resistance to
antidepressants is related to several factors like the dysregula-
tion of the hypothalamus-pituitary-adrenal (HPA) axis (Belzung
and Billette de Villemeur, 2010) or reduced hippocampal adult
neurogenesis (Santarelli et al., 2003; El-Hage et al., 2013).
Recently, we have shown that newborn hippocampal neurons are
necessary to enable chronic antidepressants to counteract stress-
induced HPA dysfunction (Surget et al., 2011). However, there
are no reliable data enabling to link HPA-related antidepres-
sant resistance to alterations in hippocampal cell proliferation
or neurogenesis, which may be due to lack of validated animal
models.
The unpredictable chronic mild stress (UCMS) model of
depression has been widely used in antidepressant screening
(Garcia et al., 2010; Nollet et al., 2013). This model was developed
in order to mimic a variety of neurochemical and behavioral
alterations similar to the ones seen in the human depressive
disorder (Jindal et al., 2013; Nollet et al., 2013). It has been also
shown to elicit HPA axis dysregulation (Surget et al., 2011) similar
to the one seen in depressed subjects (Heim et al., 2000; Belzung
and Billette de Villemeur, 2010) as well as decreased hippocampal
neurogenesis (Surget et al., 2008, 2011).
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The objective of the present study was (1) to design an
animal model of HPA-related antidepressant resistance; and
(2) to use this model to investigate the relationship between




Male BALB/cByJ mice aged 7 weeks (n = 52) at their arrival in
the laboratory were used. All mice were acquired from the Centre
d’Elevage Janvier (Le Genest Saint Isle, France). After arrival at
the lab, animals were group-housed (4–5 per cage) and kept
under standard conditions (12/12 h light-dark cycle with lights
on at 9:00, off at 21:00, room temperature: 22◦ ± 1◦C, food and
water ad libitum) in standard cages (42 cm × 27 cm × 16 cm)
with a shelter and a tube for 1 week prior to the start of the
experiment. All animal’s care and treatment were in accordance
with the European Community Council directive 86/609/EEC.
UNPREDICTABLE CHRONIC MILD STRESS (UCMS)
Mice were daily subjected to various stressors usually in the
morning and in the afternoon according a semi-random schedule
for 9 weeks. 1 week after their arrival at the lab, mice were
isolated in individual cages (24 cm × 11 cm × 12 cm) in order
to prevent them of injuries related to UCMS-related agression.
The stressors used consisted of dampened sawdust, substitution
of sawdust with water at 21◦C, removal of sawdust, tilting the
cage by 45◦C, restraint stress, repeated changes of sawdust, alter-
ations of the light and dark cycle, placing a mousse into a cage
that has been occupied by another mouse and predator sounds
(Surget and Belzung, 2008). After 2 weeks of stress exposure,
we measured the regulation of the HPA axis using the dexam-
ethasone suppression test. Median of dexamethasone-induced
suppression was 71.54%. According to the percentage of corti-
costerone suppression after dexamethasone injection, we divided
the mice into two groups (Figure 1): High suppression (HS)
and Low suppression (LS) according to the median. In order to
better segregate both groups, the animals whose dexamethasone
suppression score was 10% higher or lower than the median
(71.54 +/− 7.15) were excluded, which corresponded to 18 mice.
Therefore, final number of mice was n = 34 (17 HS and 17 LS).
From the 5th week onwards, we administered either vehicle or
fluoxetine at 15 mg/kg (ip) daily. At the end of 8th week, we
applied behavioral tests. Four mice died before the behavioral
testing occurred. Mice were sacrificed after 9 weeks of exposure
to UCMS.
DEXAMETHASONE SUPPRESSION TEST
The dexamethasone suppression test was done after 2 weeks of a
drug-free UCMS as well as at the end of the 9 weeks. Dexametha-
sone has been extensively used to probe HPA axis feedback. Mice
were injected with Dexamethasone-Phosphate (D-1759, Sigma-
Aldrich) 0.1 mg/kg or vehicle (0.9% NaCl) intraperitoneally (ip)
on two separate occasions: if mice were treated with vehicle at
the first occasion, after 2 days the same mice were administered
dexamethasone in a counterbalanced way, so that half mice in
each experimental group were treated first with vehicle and the
other half first with dexamethasone. 30 min after these injections,
the mice were subjected to open field exploration for 5 min.
Blood was collected from submandibular region (submandibu-
lar bleeding targets the point where the orbital veins join the
submandibular vein to form the jugular vein) 2 h after each
injection in EDTA added cones. Blood was centrifuged at 5000
rpm for 10 min and plasma was pipetted for conservation at
−80◦C. Corticosterone dosage was done by radioimmunoassay
using corticosterone 125Ikit (MP Biomedicals, New York, NY)
according to the manufacturer’s protocol. Radioactivity was cal-
culated using gamma counter. The percentage of suppression
was calculated as following: (the value of vehicle—the value of
dexamethasone/the value of vehicle)*100. The dexamethasone
test was done after 2 weeks of UCMS and a second time at the
end of the UCMS protocol (Figure 2). Regarding the dosage at
FIGURE 1 | Effects of 2 weeks of unpredictable chronic mild stress (UCMS) on the dexamethasone suppression. Data represent the percentage of
corticosterone suppression after dexamethasone injection HS (N = 17), LS (N = 17).
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FIGURE 2 | The experimental protocol. All mice were subjected to a
9 week UCMS. After 2 weeks of UCMS, a dexamethasone
suppression test was performed. 3 weeks later, mice were divided in
two cohorts according to their level of corticosterone suppression. The
UCMS procedure continued 5 further weeks. In each cohort, half of
the mice were treated daily with vehicle while the other half was daily
treated with fluoxetine (ip, 15 mg/kg/per day). At the end, behavioral
tests were performed as well as a second dexamethasone
suppression test. HS: High suppresser, LS: Low suppresser, VEH:
vehicle, FLX: fluoxetine.
the end of the UCMS, the data of seven mice are missing due to
technical problems.
DRUGS
The SSRI fluoxetine hydrochloride (Sequoia Research Products
Pangbourne, UK) was prepared in saline (0.9% sodium chloride).
Fluoxetine (15 mg/kg/day) and vehicle were administered ip daily
from the 5th week of the UCMS procedure until the sacrifice.
COAT STATE
The coat state of each animal was measured weekly as one of
the markers of UCMS-induced depressive-like behavior. Mice
exposed to UCMS display a progressive degradation of their coat
state. It was measured on seven body parts of the mouse: head,
neck, dorsal coat, ventral coat, tail, forepaws and hind paws. For
each body part, a score 0 was given for good state (smooth fur),
a score 0.5 was given for moderate degradation (fur with some
spiky patches) and a score 1 for unkempt coat (bad fur). The total
score given for coat state is the sum of scores obtained from the
seven body parts.
NOVELTY SUPPRESSION OF FEEDING (NSF)
The testing apparatus consisted of a wooden arena (30 × 30 ×
20 cm) with the floor covered by 2 cm of sawdust (Surget et al.,
2008). Testing was done under red light. The animals were food-
deprived 12 h before the test. At the time of testing, a single pellet
of food was placed on a white paper in the center of arena. The
animal was then placed in a corner of the arena with the head
facing the wall. The latency to start consuming the pellet was
recorded during a 3 min period as well as the frequency of sniffing.
To control for feeding drive or appetite, animals were immediately
returned to their home cage after the test and the amount of food
consumed during the subsequent 5 min was measured (home
food consumption).
SPLASH TEST
A sucrose solution was squirted onto the dorsal coat of the
animals in their home cage and the duration and the frequency
of grooming was recorded during the 5 min following the vapor-
ization (Ducottet and Belzung, 2004).
ACTOGRAPH
Home cage activity was recorded for 2 h using a photoelectric
actograph. All stressed mice were isolated 24 h before the test
to avoid activity induced by a novel environment. Home cages
were placed in the device which consisted of a 20 × 20 cm
square plane with photobeam detectors. The plane movements
were automatically detected as the animals crossed through the
detectors and a score was established.
NEST TEST
Mice were isolated in individual cage (22 cm× 16.5 cm× 14 cm),
after one Nestlet was introduced in each cage (3 g per cage). The
quality of the nest was scored 24 h after introduction of the nest
building material in the cage (Deacon, 2006; Nollet et al., 2013).
TAIL SUSPENSION TEST
Mice were suspended by the tail using adhesive tape to a rod
60 cm above the floor. The trials were conducted for a period of
6 min and were video recorded. The behavioral measure was the
duration of immobility, interpreted as behavioral despair.
SACRIFICE AND IMMUNOCHEMISTRY
Intracardiac perfusions were performed in order to investigate
cell proliferation and adult neurogenesis in the dentate gyrus
of the hippocampus. Mice were deeply anesthetized (sodium
pentobarbital 40 mg/kg i.p) and perfused through the heart with
80 ml of saline followed by 200 ml of 4% paraformaldehyde in
0.1 M PBS (ph = 7.4). Brains were removed and post fixed in
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the same fixative and cryoprotected in a 20% sucrose solution
overnight at 4◦C before being processed. Coronal sections (40µm
thickness) were cut in cryostat (Leica CM 30505) and divided
in four sections series allowing different immunohistochimical
procedures. Free floating sections were washed in 0.1 MPB, 50%
of ethanol and 3% H2O2. Sections were incubated at room tem-
perature in a rabbit anti ki-67 antibody (Abcam, ab15580, 1:1000)
followed by three washes in 0.1 M PBS and a 2 h-incubation in
secondary donkey anti-rabbit IgG biotynilated antibody (Jackson
immuno Research diluted 1:500). Then sections were incubated
in avidin-biotin-peroxidase complex (Vectastain ABC Kit, Vic-
tor Laboratories Burlingame, CA, USA, diluted 1:100) for 1 h
and reacted with freshly prepared diaminobenzidine-HCL (DAB,
Sigma—Aldrich D4293) without metal enhancement (Sigma-
Aldrich, D4293). The section were then rinsed in PB, mounted
on gelatinized glass slides, dehydrated, cleared in claral and cover
slipped with a Eukitt. All sections were counterstained with crezyl
violet (Santa Cruz, SC-214775). The same procedures were used
for doublecortin positive cells using goat anti DCX as a primary
antibody (Santa Cruz, SC-8066, 1:500) and anti goat (A-11056,
1:500) as a secondary antibody.
DATA ANALYSIS
Cell proliferation and neurogenesis were examined in the septal
(bregma −0.94 to −1.58 mm), intermediate (bregma −1.70 to
−3.28 mm) and temporal parts (bregma −3.40 to −3.88) of
the hippocampus (Franklin and Paxinos, 2008). The granule cell
layer surfaces were determined with Axiovision software from
pictures obtained at x10 objective lens at corresponding levels on
crezyl violet staining to express numbers of immunoreactive cells
per square millimeter of respective areas and finally per cubic
millimeter by multiplying by the thickness of sections (40 µm).
All quantifications were performed by an investigator blind to
stress and treatment. All sections in each part of the hippocampus
were examined with a Leica DM 2000 microscope.
STATISTICAL ANALYSIS
For behavioral tests, dexamethasone suppression and histolog-
ical analysis, group comparisons were performed using non-
parametric-tests as data did not follow a normal distribution
and variance were not homogeneous. The Kruskall-Wallis test
was performed followed by a Mann Whitney U-test including
corrections for multiple comparisons when required. For com-
parisons between vehicle and dexamethasone injection in a given
experimental group, we used Wilcoxon test. All data are expressed
as the mean± SEM.
RESULTS
EFFECTS OF FLUOXETINE ON COAT STATE AND ON BEHAVIORAL TESTS
As seen from Figure 3A, Kruskall Wallis test revealed overall
differences in the coat state after 7th and 8th weeks UCMS
(respectively H(3,34) = 22.35, p < 0.001; H(3,34) = 20.34,
p < 0.001). The results show that the UCMS-induced coat
state degradation was reversed by fluoxetine in both HS and
LS. Mann Whitney comparisons showed significant difference
between HS FLX vs. HS VEH (p < 0.01) (week 7 and week
8) and LS VEH vs. LS FLX (p < 0.01) (week 7 and week 8).
Further, significant difference was found between LS FLX vs.
HS FLX for week 7 (p < 0.05) and for week 8 (p < 0.01).
No significant difference was found between HS VEH vs. LS
VEH.
Kruskall Wallis test revealed differences among groups in the
nest building score (H(3,34) = 11.13, p < 0.01). Nest building
score was affected by fluoxetine treatment in HS VEH compared
to HS FLX (p < 0.01) while this was not seen in the LS VEH
compared to LS FLX. Further, there was a difference between HS
FLX compared to LS FLX and between HS VEH and LS VEH
(Figure 3B).
Figure 3C shows that Kruskall Wallis test revealed differences
in locomotor activity (H(3,34) = 9.61, p < 0.05). Again, the effects
of chronic fluoxetine were seen only in the HS mice (p < 0.01)
and not in the LS mice. Further, there was no difference between
LS VEH compared to LS FLX and between LS FLX compared HS
FLX but there was a difference between LS FLX compared to HS
FLX (p < 0.01).
Results of the splash test are shown on Figures 3D,E. Kruskall
Wallis test revealed difference in the frequency of grooming
(H(3,34) = 11.01, p < 0.01) as well as in the duration of grooming
(H(3,34) = 13.99, p < 0.01). For both parameters, fluoxetine
induced antidepressant-like effects both in HS and in LS mice.
Indeed, concerning frequency of grooming, the Mann Whitney
comparisons showed a significant difference between HS FLX
compared to HS VEH (p < 0.01) and the same result was found
for duration of grooming (HS VEH compared to HS FLX: p <
0.01). Further, there was a difference between LS VEH compared
to LS FLX (p < 0.01 for the frequency and p < 0.05 for the
duration of grooming). Finally, no significant differences were
found between LS FLX compared to HS FLX and for HS VEH
compared to LS VEH for duration and frequency of grooming.
Results obtained in the NSF test are shown on Figures 3F,G,H.
Frequency of sniffing and latency to eat were modified by the
treatment (respectively H(3,34) = 14.05, p < 0.01 and H(3,34) =
8.34, p< 0.01). This was related to the fact that fluoxetine elicited
behavioral effects in both HS and LS animals. Indeed, Mann
Whitney showed a significant difference between HS VEH and
HS FLX for frequency of sniffing as well as latency to eat (p <
0.01). The HS and LS control groups only differed after fluoxetine
treatment (for frequency of sniffing, p < 0.01). In addition,
Kruskall Wallis H-test revealed difference in food consumption
(H(3,34) = 11.79, p < 0.01), which was related to a decreased
consumption in the HS control group when compared to the
corresponding fluoxetine condition (p < 0.01).
Results from the tail suspension test are presented in Figure 3I.
Kruskal-Wallis H-test did not enable to reveal any statisticial
difference among groups (H(3,34) = 3.86, p = 0.276).
EFFECTS OF UCMS AND PHARMACOLOGICAL TREATMENTS ON HPA
AXIS FUNCTION
Results indicate that after 2 weeks of drug-free UCMS, the basal
corticosterone level was higher in the HS group compared to
LS group (p < 0.001) (Figure 4A); this difference disappeared
after dexamethasone. Further, at that time point, dexametha-
sone reduced the corticosterone level in both groups (Wilcoxon
comparison: VEH vs. DEX for HS group T = 25, P < 0.001;
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FIGURE 3 | Effects of UCMS and 4 weeks fluoxetine treatment
(15 mg/kg/per day) (FLX) or Vehicle (VEH) on the behavior in High
suppresser (HS) and Low suppresser (LS) mice (HS VEH (n = 10),
HS FLX (n = 7), LS VEH (n = 11), LS FLX (n = 6). (A) Coat state (B)
Nest test (C) Locomotor activity. (D) Frequency of grooming in the
splash test. (E) Duration of gooming in splash test. (F) Food
consumption in novelty suppression of feeding. (G) Frequency of
sniffing in novelty suppression of feeding. (H) Latency to eat in the
novelty suppression of feeding test. (I) Immobility in the tail
suspension test. HS FLX vs. LS FLX: * p < 0.05, ** p < 0.01; HS FLX
vs. HS VEH: # p < 0.05, ## p < 0.01, ### p < 0.001; LS FLX vs. LS VEH:
££ p < 0.01.
VEH vs. DEX for LS group T = 0.00, P < 0.01). In addition,
the dexamethasone suppression was different in the HS group
compared to the LS group (p < 0.001) (Figure 4B).
At the end of the UCMS protocol, the four groups were
not different statistically for basal corticosterone, corticosterone
after dexamethasone (Figure 4C) and dexamethasone-induced
corticosterone suppression H(3,27) = 5.39, p > 0.05 (Figure 4D).
Regarding the vehicle-dexamethasone comparisons in each exper-
imental condition, Wilcoxon test revealed differences in all groups
(T = 0.0, P < 0.05 for HS VEH batch, T = 0.00, p < 0.01 for LS
VEH batch, T = 0.0, p< 0.05 for LS FLX batch) except for the HS
FLX condition (T = 6, p > 0.5).
HIPPOCAMPAL CELL PROFIFERATION AND NEUROGENESIS AFTER
PHARMACOLGICAL TREATMENT
As seen from Figure 5A, Kruskall Wallis H-test revealed a signifi-
cant difference in cell proliferation among groups in the different
regions of the granule cell layer of the dentate gyrus (whole
dentate gyrus: H(3,28) = 13.84; p < 0.01; septal dentate gyrus:
H(3,23) = 7.46; p < 0.05; intermediate dentate gyrus: H(3,28) =
14.04; p < 0.01 and temporal dentate gyrus: H(3,28) = 12.47;
p < 0.01). Overall, fluoxetine induced a marked increase of the
density of ki-67 positive cells only in the HS subgroup. Mann
Whitney showed significant difference between HS VEH vs. HS
FLX in the whole of dentate gyrus (p < 0.001), the septal region
(p < 0.05), the intermediate region (p < 0.001) and the temporal
region of the dentate gyrus (p< 0.001). No effect of fluoxetine was
seen in the LS group in the different parts of the hippocampus. HS
and LS markedly differed only after fluoxetine.
Concerning doublecortin positive cells (see Figure 5B),
Kruskall Wallis H-test revealed significant differences in all
regions of the hippocampus (whole dentate gyrus: H(3,21) = 10.37,
p < 0.05; septal part: H(3,20) = 9.13; p < 0.05; intermediate part
H(3,20) = 1.49, p < 0.01; temporal part: H(3,21) = 7.91; p < 0.05).
No effects of fluoxetine were observed in HS or LS mice. Further,
there was no difference between HS VEH and HS FLX. Finally,
there was a difference between HS FLX and LS FLX in the whole
(p < 0.01), the septal (p < 0.01), the intermediate (p < 0.01) and
the temporal region p< 0.01, the DCX labeling being lower in the
HS mice.
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FIGURE 4 | Effects of UCMS and 4 week treatment with fluoxetine
(15 mg/kg/day) on the dexamethasone (DEXA) suppression test after
vehicle or dexamethasone injection. HS: High suppressers, LS: Low
suppressers, VEH: vehicle, FLX: fluoxetine. (A) Corticosterone after injection
of vehicle or dexamethasone after 2 weeks of UCMS. (B) Suppression rate of
corticosterone after 2 weeks of UCMS. (C) Corticosterone after injection of
vehicle or dexamethasone at the end of UCMS. (D) Suppression rate after 9
weeks of UCMS. Figures 4A,B: n = 17 in each experimental condition.
Figures 4C,D: HS VEH (n = 10), HS FLX (n = 7), LS VEH (n = 11), LS FLX
(n = 6). HS vs. the corresponding LS condition: &&& p < 0.001; basal
corticosterone vs. corresponding dexamethasone-induced corticosterone:
$ p < 0.05, $$ p < 0.01, $$$ p < 0.001.
Representative pictures of ki-67 and DCX labeling can be seen
from Figure 6.
DISCUSSION
In this experiment we studied the contribution of HPA axis
dysregulation in creating resistance to antidepressants using
an animal model of major depression. We tested the effect of
fluoxetine in two groups based on the suppression of corticos-
terone following dexamethasone administration after an initial
period of stress. Our results demonstrate that fluoxetine-induced
antidepressant effects were observed with higher amplitude in a
group initially characterized as HS when compared to a group
initially characterized as LS in various behavioral tests such as the
nest test, the actograph and the novelty suppression of feeding.
This absence of antidepressant-like effects of fluoxetine in the LS
group mimicked the antidepressant resistance seen in humans in
whom failure of SSRI to induce remission has been observed in
correlation with a defect of the regulation of the HPA axis. We can
therefore propose that mice from the LS group can be considered
as a way to induce HPA-related antidepressant resistance. It is
however important to indicate that this resistance observed in the
LS group does not concern all aspects of the phenotype. Indeed,
the effects of fluoxetine were still present on the coat state (even
if the amplitude of the effects is lower) and in the splash test,
two phenotypes related to grooming behavior. This suggests that
there is a clear dissociation between the mechanisms underlying
the effects of fluoxetine on grooming-related behavior and the
mechanisms underlying the other behavioral actions of the SSRI.
Phenotyping the UCMS-induced anhedonia would be necessary
to enable to further characterize the effects of the SSRI in HS and
LS mice. Further, it is interesting to note that the behavior of mice
from the vehicle-treated HS and the vehicle-treated LS groups did
not differ after vehicle treatment, indicating that the contribution
of the HPA regulation is specific to the antidepressant’s effects.
Further, we found that chronic fluoxetine treatment was able
to increase cell proliferation in the dentate gyrus of the hippocam-
pus in mice from the HS group. This result is in agreement with
previous findings (Santarelli et al., 2003; Airan et al., 2007; Wang
et al., 2008). This effect was observed at all levels of the dentate
gyrus, from the more septal to the more temporal ones. Interest-
ingly, in mice from the LS group, fluoxetine was unable to increase
cell proliferation. Therefore, the inability of fluoxetine to induce
behavioral effects in mice from the LS group correlated with a fail-
ure to increase cell proliferation in the hippocampus, suggesting
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FIGURE 5 | Effects of UCMS and 4 weeks treatment of fluoxetine
(FLX 15 mg/kg/day ip) on cell proliferation and neurogenesis in the
hippocampus. HS: High suppressers, LS: Low suppressers, VEH:
vehicle, FLX: fluoxetine. (A) Densitiy of cell proliferation using ki-67
staining in the granule cell layer in the whole, dorsal, intermediate, and
ventral hippocampus (whole, temporal and intermediate hippocampus:
HS VEH (n = 9), HS FLX (n = 6), LS VEH (n = 7), LS FLX (n = 6); septal
hippocampus: HS VEH (n = 7), HS FLX (n = 6), LS VEH (n = 7), LS FLX
(n = 5)). (B) Density of immature neurons using doublecortin (DCX)
labeling in the GCL (whole, temporal and intermediate parts: HS VEH
(n = 5), HS FLX (n = 6), LS VEH (n = 6), LS FLX (n = 4); septal parts:
HS VEH (n = 5), HS FLX (n = 5), LS VEH (n = 6), LS FLX (n = 4)). HS
VEH vs. HS FLX: # p < 0.05, ### p < 0.001; HS FLX vs. LS FLX:
* p < 0.05, ** p < 0.01.
a possible mechanism underlying the antidepressant-resistance.
However, it is important here to consider that, as indicated above,
fluoxetine was able to modify grooming and coat state in mice
from the LS group, suggesting that these two effects are inde-
pendent of hippocampal cell proliferation. This confirmed the
dissociation between neurogenesis-dependent and independent
effects, which have been observed previously by our group (Surget
et al., 2008) and others (Bessa et al., 2009; David et al., 2009;
Mateus-Pinheiro et al., 2013). Interestingly also, the level of cell
proliferation was unrelated to the basal corticosterone levels, as
the increase in cell proliferation observed in the HS fluoxetine
group was not associated to a decreased basal corticosterone.
In the present study, fluoxetine was unable to alter
doublecortin labeling in mice from both the LS and HS groups.
This finding has already been observed by others (see for example
David et al., 2010) and might be related to the fact that fluoxetine
accelerates the maturation of the newborn cells. Indeed, others
showed that fluoxetine does not increase the number of dou-
blecortin positive cells, but increases the fraction of doublecortin-
positive cells possessing tertiary dendrites (David et al., 2010).
Concerning basal corticosterone and dexamethasone
suppression test, we segregated the mice according to the
dexamethasone suppression level observed after 2 weeks of stress.
Interestingly, this fully overlapped with the basal corticosterone
values observed at this time point, as HS overlaps with high basal
corticosterone. Thus it is possible that the absence of suppression
in mice from the LS group could be related to a ceiling effect,
as it might be difficult to further reduce the corticosterone level
in this group. Further, the high basal corticosterone exhibited
by mice of the HS group could relate either to an initial
difference present before the beginning of the UCMS, or to an
increased vulnerability to stress in mice from this group. The data
concerning corticosterone levels and dexamethasone suppression
at the end of the 9 weeks of UCMS can be interpreted within this
frame. Indeed, the basal corticosterone levels observed in control
mice of the LS group at the end of the UCMS are equivalent to
the ones of the mice from the HS group after 2 weeks of UCMS.
Therefore, it is possible that the elevated corticosterone level
observed in mice of the HS group after 2 weeks of UCMS could
not be further increased. At the end of the UCMS, dexamethasone
could induce corticosterone suppression due to the high basal
levels of corticosterone present in all groups.
How can we explain that fluoxetine induced some behavioral
effects and an action on cell proliferation in the HS, but not in
the LS group? We think that the inability of fluoxetine to increase
cell proliferation in mice of the LS group might certainly explain
the failure of the antidepressant to induce behavioral effects. In
fact, we propose that in HR mice, the high level of corticosterone
observed after 2 weeks of UCMS might have induced a decrease
in hippocampal glucocorticoid receptors (GRs), both in adult
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FIGURE 6 | Representative pictures of ki67 (6A) and DCX (6B) labeling
in the dentate gyrus of the hippocampus. HS: High suppressers, LS:
Low suppressers, VEH: vehicle, FLX: fluoxetine.
granule and progenitor cells. This downregulation of GRs in the
progenitor cells might then have accelerated the maturation of
newborn neurons, as such an effect has already been observed
(Fitzsimons et al., 2013), eliciting the behavioral effects. This
effect of corticosterone would not be present in the mice from the
LS group displaying low corticosterone after 2 weeks of UCMS.
However, this is purely speculative and further assays, such as
quantification of GRs in our two groups, should confirm the
present interpretation.
In conclusion, these data suggest that dysregulation of the
HPA axis is associated with antidepressant resistance. Even if
the data are only correlative, they suggest that this fluoxetine
non-response is related to poor ability of the SSRI to stimu-
late cell proliferation in the dentate gyrus. Further studies are
necessary to investigate the causal relationship between these
phenomenons.
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